Format

Send to

Choose Destination
J Surg Oncol. 2009 Sep 15;100(4):331-4. doi: 10.1002/jso.21321.

Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients.

Author information

1
Department of Surgical Oncology, Digestive Branch, Regina Elena National Cancer Institute, Rome, Italy.

Abstract

Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.

PMID:
19697441
DOI:
10.1002/jso.21321
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center